MLN8237 (alisertib), an investigational Aurora A Kinase inhibitor, in patients with breast cancer: Emerging phase 2 results

被引：0
|
作者：
Alvarez, R. H.
DeMichele, A.
Mailliez, A.
Benaim, E.
Fingert, H.
Schusterbauer, C.
Zhang, B.
Melichar, B.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Abramson Canc Ctr, Philadelphia, PA USA
[3] Ctr Oscar Lambret, F-59020 Lille 59, France
[4] Millennium Pharmaceut Inc, Cambridge, MA USA
[5] Fak Nemocnice Olomouc, Onkol Klin, Olomouc, Czech Republic
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/0008-5472.SABCS12-P6-10-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-10-02
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose
    Venkatakrishnan, Karthik
    Kim, Tae Min
    Lin, Chia-Chi
    Thye, Lim Soon
    Chng, Wee Joo
    Ma, Brigette
    Chen, Ming Huang
    Zhou, Xiaofei
    Liu, Hua
    Kelly, Virginia
    Kim, Won Seog
    INVESTIGATIONAL NEW DRUGS, 2015, 33 (04) : 942 - 953
  • [2] Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose
    Karthik Venkatakrishnan
    Tae Min Kim
    Chia-Chi Lin
    Lim Soon Thye
    Wee Joo Chng
    Brigette Ma
    Ming Huang Chen
    Xiaofei Zhou
    Hua Liu
    Virginia Kelly
    Won Seog Kim
    Investigational New Drugs, 2015, 33 : 942 - 953
  • [3] Phase 2 study of single agent MLN8237 (alisertib), an investigational aurora A kinase (AAK) inhibitor, in patients (pts) with relapsed/refractory breast cancer (BrC)
    Melichar, B.
    DeMichele, A.
    Adenis, A.
    Bourbouloux, E.
    Tan-Chiu, E.
    Niu, H.
    Schusterbauer, C.
    Ullmann, C. Dansky
    Zhang, B.
    Benaim, E.
    CANCER RESEARCH, 2013, 73
  • [4] Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors
    Falchook G.S.
    Zhou X.
    Venkatakrishnan K.
    Kurzrock R.
    Mahalingam D.
    Goldman J.W.
    Jung J.A.
    Ullmann C.D.
    Milch C.
    Rosen L.S.
    Sarantopoulos J.
    Drugs in R&D, 2016, 16 (1) : 45 - 52
  • [5] Results From a Phase 1 Multicenter Trial of Alisertib (MLN8237)-An Investigational Aurora A Kinase Inhibitor-in Patients with Advanced Hematologic Malignancies
    Kelly, Kevin R.
    Padmanabhan, Swaminathan
    Goy, Andre
    Berdeja, Jesus G.
    Reeder, Craig B.
    McDonagh, Kevin T.
    Zhou, Xiaofei
    Danaee, Hadi
    Xiao, Hugh
    Benaim, Ely
    Shea, Thomas C.
    BLOOD, 2011, 118 (21) : 1061 - 1062
  • [6] FOOD EFFECT STUDY OF THE INVESTIGATIONAL AURORA A KINASE (AAK) INHIBITOR MLN8237 (ALISERTIB) IN PATIENTS WITH ADVANCED SOLID TUMORS
    Falchook, G. S.
    Zhou, X.
    Rosen, L. S.
    Venkatakrishnan, K.
    Kurzrock, R.
    Mahalingam, D.
    Goldman, J.
    Jung, J.
    Milch, C.
    Sarantopoulos, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 168 - 168
  • [7] Effects of alisertib (MLN8237), an investigational Aurora A kinase inhibitor (AAKi), on the QTc interval in patients (pts) with advanced malignancies
    Zhou, X.
    Nemunaitis, J.
    Pant, S.
    Bauer, T. M.
    Patel, M.
    Sarantopoulos, J.
    Lockhart, A. C.
    Goodman, D.
    Zhang, B.
    Ullmann, C. Dansky
    Mould, D. R.
    Venkatakrishnan, K.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S76 - S77
  • [8] Phase I Study of An Investigational Aurora A Kinase Inhibitor MLN8237 In Patients with Advanced Hematologic Malignancies
    Padmanabhan, Swaminathan
    Shea, Thomas C.
    Vose, Julie M.
    Reeder, Craig B.
    Berdeja, Jesus G.
    McDonagh, Kevin T.
    Goy, Andre
    Kelly, Kevin R.
    Zhou, Xiaofei
    Liu, Hua
    Fingert, Howard
    Fowler, Nathan
    BLOOD, 2010, 116 (21) : 1154 - 1154
  • [9] Development of a phase 2 study of the aurora kinase-A inhibitor alisertib (MLN8237) in pretreated patients (pts) with urothelial cancer (UC).
    Necchi, Andrea
    Mariani, Luigi
    Giannatempo, Patrizia
    Raggi, Daniele
    Fare, Elena
    Marchlano, Alfonso
    Crippa, Flavlo
    Togllardi, Elena
    Daldone, Maria Grazla
    Gianni, Alessandro M.
    Salvioni, Roberto
    De Braud, Filippo G.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [10] MLN8237 (ALISERTIB), A SELECTIVE AURORA A KINASE (AAK) INHIBITOR, IN PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC): PHASE 2 RESULTS
    Havel, Libor
    Dees, Claire
    Lockhart, Craig
    Bennouna, Jaafar
    Serwatowski, Piotr
    Liu, Stephen
    Niu, Huifeng
    Badola, Sunita
    Schusterbauer, Claudia
    Ullmann, Claudio Dansky
    Zhang, Bin
    Benaim, Ely
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S221 - S222
12345